Interview with Tan Yew Chin, Chief Executive Officer, Ascendas
As a pioneering member of Arcasia, before it merged with JTC International and became what is Ascendas today, you know the history of the company very intimately. What are the…
Address: 61 Science Park Road, #04-01 The Galen.Singapore Science Park II, Singapore 117525,Singapore
Tel: +65 6774 1033
Web: http://www.ascendas.com/english/
Ascendas is Asia’s leading provider of business space solutions with more than 30 years of experience across the region. Based in Singapore, Ascendas has built a strong regional presence and serves a global clientele of over 2,400 customers in 33 cities across 10 countries including Singapore, China, India, South Korea and Australia.
Ascendas specializes in masterplanning, developing, managing and marketing IT parks, industrial & logistics parks, business parks, science parks, hi-tech facilities, office and retail space for a host of industries. Leveraging on its track record and experience, Ascendas has introduced new business space concepts such as integrated communities and solutions which seamlessly combine high-quality business, lifestyle, retail and hotel spaces to create conducive human-centric work-live-play-learn environments. Its flagship projects include the Singapore Science Park, International Tech Park Bangalore in India, Dalian-Ascendas IT Park in China and Carmelray Industrial Park II in the Philippines.
Asia’s leading provider of business space solutions. The company provides end-to-end real estate solutions, assisting corporate customers through the entire real estate process.
As a pioneering member of Arcasia, before it merged with JTC International and became what is Ascendas today, you know the history of the company very intimately. What are the…
Erika Pagani, country manager for Pfizer Singapore, shares her journey with the company from Brazil to New York, Peru, Ecuador, and finally Singapore. She discusses why the island city-state is…
Beh Kian Teik of Singapore’s National Research Foundation (NRF) outlines the importance of the life sciences within the country’s innovation strategy and the role it has to play at a…
EY’s Abhay Bangi highlights the key trends across the ASEAN life sciences space, how the COVID-19 pandemic has accelerated them, and charts Singapore’s course towards becoming a world-class biotech investment…
Innovation is at the heart of healthcare transformation and the doors for a much-needed shift from provider- to patient-centric solutions have been opened. That is the idea behind HealthBeats™, a…
Simranjit Singh highlights Guardant Health’s role in the global precision oncology landscape and how the company leverages its proprietary blood tests, vast data sets, and advanced analytics across the huge…
John Baby of home rehabilitation device start-up WO:EX outlines how his firm’s products differ from others on the market through their multifunctionality, its expansion plans in Asia and Australia, and…
Dr Varun Sethi outlines some of the most important trends in ASEAN healthcare today and how DKSH, as a historic business services provider, is adapting its offering to meet them.…
Since 2000, when Singapore first positioned biomedical research as the fourth pillar of the country’s economy, government funding towards innovative life sciences start-ups and spin-offs has dramatically increased. These companies…
Annie Tan highlights the strategy she laid out to navigate the BMS Singapore, Thailand and Malaysia affiliates through the COVID-19 pandemic; the opportunities and challenges of integrating the Celgene portfolio…
Kenneth Tan has been President for Asia Pacific & Japan at cancer-focused medical device player Varian since February 2019. In a recent conversation with PharmaBoardroom, Tan shared how an early…
Professor Ng Huck Hui of A*Star’s Biomedical Research Council outlines the evolution of Singapore’s science and technology research and innovation ecosystem over the past 20 years and why the country…
Dr Piers Ingram, PhD, co-founder, and CEO of Singapore-based biotech Hummingbird Bioscience, shares his motivation for establishing the company in 2015, their proprietary Rational Antibody Discovery (RAD) technology platform, and…
See our Cookie Privacy Policy Here
